A recent target trial emulation among veterans with type 2 diabetes found that adding GLP-1 receptor agonists to basal insulin therapy did not improve insulin discontinuation rates. Researchers compared the effects of adding GLP-1RAs against adding SGLT-2i or DPP-4i therapy, but saw no significant difference in outcomes.